Voyager Therapeutics, Inc. (VYGR) Stock Price Down 1.3% After Insider Selling
Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) dropped 1.3% during trading on Monday following insider selling activity. The stock traded as low as $12.25 and last traded at $13.60. Approximately 1,005,100 shares changed hands during mid-day trading, an increase of 351% from the average daily volume of 223,100 shares. The stock had previously closed at $13.43.
Specifically, insider Bernard Ravina sold 16,470 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.87, for a total transaction of $211,968.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 38,430 shares of company stock valued at $562,890. 8.00% of the stock is currently owned by corporate insiders.
Several research firms have recently weighed in on VYGR. ValuEngine cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. Chardan Capital reissued a “hold” rating and set a $17.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, Evercore ISI initiated coverage on shares of Voyager Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $12.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $27.88.
Several institutional investors have recently added to or reduced their stakes in VYGR. Wells Fargo & Company MN lifted its stake in shares of Voyager Therapeutics by 312.8% in the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after buying an additional 285,806 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Voyager Therapeutics in the third quarter valued at $5,155,000. DAFNA Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 187.2% in the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after buying an additional 133,488 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new position in shares of Voyager Therapeutics in the third quarter valued at $1,412,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Voyager Therapeutics by 232.0% in the second quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock valued at $879,000 after buying an additional 68,574 shares in the last quarter. 40.93% of the stock is currently owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.